Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:20:57 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:SPRO - SPERO THERAPEUTICS INC - https://www.sperotherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SPRO - Q0.81.53·1.800.11.59+0.021.3178.72624291.60  1.6055  1.531.94  0.9917:25:27May 1615 min RT 2¢

Recent Trades - Last 10 of 429
Time ETExPriceChangeVolume
17:25:27Q1.590.02227
17:24:15Q1.590.02173
16:00:00Q1.590.022,480
16:00:00Q1.590.02100
16:00:00Q1.590.0214
16:00:00Q1.590.0214
16:00:00Q1.590.021
16:00:00Q1.590.0214
16:00:00Q1.590.0265
16:00:00Q1.590.02200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-16 16:05U:SPRONews ReleaseSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
2024-05-15 16:06U:SPRONews ReleaseSpero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
2024-05-08 08:00U:SPRONews ReleaseSpero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
2024-05-01 16:08U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 16:01U:SPRONews ReleaseSpero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
2024-03-06 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
2024-02-28 08:05U:SPRONews ReleaseSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
2024-02-26 08:05U:SPRONews ReleaseSpero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
2024-01-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 08:05U:SPRONews ReleaseSpero Therapeutics Provides Corporate Update and 2024 Outlook
2024-01-02 08:05U:SPRONews ReleaseSpero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial ‚  Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
2023-11-13 16:05U:SPRONews ReleaseSpero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
2023-11-06 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
2023-11-01 16:05U:SPRONews ReleaseSpero Therapeutics to Present at Upcoming November Investor Conferences
2023-11-01 08:05U:SPRONews ReleaseSpero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
2023-10-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-29 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-20 16:05U:SPRONews ReleaseSpero Therapeutics to Present at Cantor ¢ € ™s Global Healthcare 2023 Investor Conference
2023-09-12 08:00U:SPRONews ReleaseSensorium Therapeutics Appoints Veteran Life Sciences Executive ‚  Mr. David Southwell to its Board of Directors
2023-09-06 08:05U:SPRONews ReleaseSpero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference